<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2003-9-1-10-13</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-865</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Клинические и вазопротективные эффекты аспирина у больных, длительно получающих терапию ингибиторами ангиотензинпревращающего ферментгу</article-title><trans-title-group xml:lang="en"><trans-title>The clinical and vasoprotective effect of aspirin in patients long receiving therapy with angiotensin-converting enzyme inhibitors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ситникова</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Sitnikova</surname><given-names>M. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимова</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimova</surname><given-names>T. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вахрамеева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vakhrameyeva</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хмельницкая</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khmelnitskaya</surname><given-names>K. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Научно-исследовательский институт кардиологии им. В.А. Алмазова Минздрава РФ; СПбГМУ им. акад. И.П.Павлова, Санкт-Петербург</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2003</year></pub-date><pub-date pub-type="epub"><day>28</day><month>02</month><year>2003</year></pub-date><volume>9</volume><issue>1</issue><fpage>10</fpage><lpage>13</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ситникова М.Ю., Максимова Т.А., Вахрамеева Н.В., Хмельницкая К.А., 2003</copyright-statement><copyright-year>2003</copyright-year><copyright-holder xml:lang="ru">Ситникова М.Ю., Максимова Т.А., Вахрамеева Н.В., Хмельницкая К.А.</copyright-holder><copyright-holder xml:lang="en">Sitnikova M.Y., Maksimova T.A., Vakhrameyeva N.V., Khmelnitskaya K.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/865">https://htn.almazovcentre.ru/jour/article/view/865</self-uri><abstract><p>У 45 мужчин с ишемической болезнью сердца (ИБС) и проявлениями хронической сердечной недостаточности (XCH) в рамках открытого ретроспективного исследования была проведена б-месячная терапия ингибиторами ангиотензинпревращающего фермента (ИАПФ), из них 30 больных на протяжении 6 мес дополнительно получали ацетилсалициловую кислоту в дозе 125 мг в сутки. В динамике оценивали клинические показатели, толерантность к физической нагрузке, данные эхокардиграфического исследования и основные маркеры состояния эндотелия: содержание эндотелина-1 (ЭТ-1), циркулирующих в крови десквамированных эндотелиоцитов (ЦЭК), эндотелийзависимую вазодилатацию, уровень мочевой кислоты, содержание интерлейкина-8 (ИЛ-8). По результатам исследования сделаны выводы о том, что у больных ИБС с проявлениями XCH сопутствующая терапия аспирином не ослабляет основные клинические эффекты ИАПФ и способствует уменьшению функционального класса стенокардии, уменьшению встречаемости парадоксальной вазоконстрикции плечевой артерии. Аспирин в суточной дозе 0,125 ед. не сказывается отрицательно на динамике систолической функции левого желудочка, показателях вазодилатации плечевой артерии, динамике уровней ЭТ-1, ЦЭК, ИЛ-8 и мочевой кислоты в крови, но в то же время умеренно ослабляет гипотензивный эффект ИАПФ.</p></abstract><trans-abstract xml:lang="en"><p>During an open retrospective study, 6-month therapy with angiotensin-converting enzyme inhibitors (ACEl) was performed in 45 males with coronary heart disease (CHD) and manifestations of chronic heart failure (CHF)1 of them 30 patients additionally received acetyl-salicylic acid in a daily dose of 125 mg. Clinical parameters, exercise tolerance, echocardiographic data and the major endothelial markers: the level of endothelin-1 (ET-1), blood circulating desquamated endotheliocytes (CDE), endothelium-dependent vasodilatation, the level of uric acid, the content of interleukin-8 (1L-8), were followed up. The findings have led to the conclusion that in patients with CHD and manifestations of CHF, contaminant aspirin therapy does not decrease the main clinical effects of ACEl and it contributes to a reduction in the functional class of angina pectoris, in the incidence of paradoxical vasoconstriction of the brachial artery. Aspirin in a daily dose of 0.12 5 fails to have a negative effect on the variations of left ventricular systolic function, on the parameters of brachial vasodilatation, on the changes in the blood levels of ET-1, CDE, 1L-8, and uric acid, but moderately decreases the antihypertensive effect of ACEI at the same time.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>ИАПФ</kwd><kwd>ацетилсалициловая кислота</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>цитокины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart disease</kwd><kwd>angiotensin-converting enzyme inhibitors</kwd><kwd>acetylsalicylic acid</kwd><kwd>endothelial dysfunction</kwd><kwd>cytokines</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">NawarskasJJ, Spinier SA. Pharmacotherapy 1998; 18:1041-52.</mixed-citation><mixed-citation xml:lang="en">NawarskasJJ, Spinier SA. Pharmacotherapy 1998; 18:1041-52.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival StudyII (CONSENSUS II). Am J Cardiol 1997;79:115-9.</mixed-citation><mixed-citation xml:lang="en">Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival StudyII (CONSENSUS II). Am J Cardiol 1997;79:115-9.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Coats AJS.Enalapril, aspirin interaction fletter J.Am J Cardiol 1997; 80:1122.</mixed-citation><mixed-citation xml:lang="en">Coats AJS.Enalapril, aspirin interaction fletter J.Am J Cardiol 1997; 80:1122.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Leor J, Reicher-Reiss H, Goldbourt U et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11575 patients with coronary artery disease.JAm Coll Cardiol 1999; 33:1920-5-</mixed-citation><mixed-citation xml:lang="en">Leor J, Reicher-Reiss H, Goldbourt U et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11575 patients with coronary artery disease.JAm Coll Cardiol 1999; 33:1920-5-</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hall D, Zeitler H, Rudolph W. JAm Coll Cardiol 1992; 20:1549-55-</mixed-citation><mixed-citation xml:lang="en">Hall D, Zeitler H, Rudolph W. JAm Coll Cardiol 1992; 20:1549-55-</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Teerlink JR, Massie BM. The interaction of ACE inhibitors and aspirin in heart failure: tom between tivo lovers.Am HeartJ 1999; 138:193-7-</mixed-citation><mixed-citation xml:lang="en">Teerlink JR, Massie BM. The interaction of ACE inhibitors and aspirin in heart failure: tom between tivo lovers.Am HeartJ 1999; 138:193-7-</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г.П., Розанов A.В. Некоторые аспекты совместного применения ацетилсалициловой кислоты и ингибиторов АПФ у больных в постинфарктном периоде. Клин. фарм. тер, 2000; 9 (4): 16-8.</mixed-citation><mixed-citation xml:lang="en">Арутюнов Г.П., Розанов A.В. Некоторые аспекты совместного применения ацетилсалициловой кислоты и ингибиторов АПФ у больных в постинфарктном периоде. Клин. фарм. тер, 2000; 9 (4): 16-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Siraluddin RA, Miller AB, Geraci SA. Anticoagulation in patient with dilated cardiomiopathy and sinus rhythm: a critical review. J Card Failure 2002; 8 (I): 48-53</mixed-citation><mixed-citation xml:lang="en">Siraluddin RA, Miller AB, Geraci SA. Anticoagulation in patient with dilated cardiomiopathy and sinus rhythm: a critical review. J Card Failure 2002; 8 (I): 48-53</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nawarskas JJ, Tоwnsend RR, Cirigliano MD, Spinier SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril orlosartan.Am J Hypertens 1999; 12: 784-9-</mixed-citation><mixed-citation xml:lang="en">Nawarskas JJ, Tоwnsend RR, Cirigliano MD, Spinier SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril orlosartan.Am J Hypertens 1999; 12: 784-9-</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Guazzi M, Pontone G.Piergiuseppe A.Aspirin vorsnes exercise performans and pulmonare gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors.Am HeartJ 1999; 138 (138): 254-60.</mixed-citation><mixed-citation xml:lang="en">Guazzi M, Pontone G.Piergiuseppe A.Aspirin vorsnes exercise performans and pulmonare gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors.Am HeartJ 1999; 138 (138): 254-60.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nawarskas JJ, Spinier SA. Update on the Interaction BetweenAspirin and Angiotensin-Converting Enzyme Inhibitors. Pharmacotherapy 2000; 20 (6): 698-710.</mixed-citation><mixed-citation xml:lang="en">Nawarskas JJ, Spinier SA. Update on the Interaction BetweenAspirin and Angiotensin-Converting Enzyme Inhibitors. Pharmacotherapy 2000; 20 (6): 698-710.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">AI-Khadra A, Salem D, Rand W. Antiplatelet agents and survival: a cohort analysisfrom the studies of left ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31:419-25.</mixed-citation><mixed-citation xml:lang="en">AI-Khadra A, Salem D, Rand W. Antiplatelet agents and survival: a cohort analysisfrom the studies of left ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31:419-25.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Isnard R, Baroin J-P, Drobinski G et al. Influence of aspirin on long-term prognosis of patients with ischemic left ventricular systolic dysfunction [abstr]. Circulation 1998; 98 (suppl.I): 1-300.</mixed-citation><mixed-citation xml:lang="en">Isnard R, Baroin J-P, Drobinski G et al. Influence of aspirin on long-term prognosis of patients with ischemic left ventricular systolic dysfunction [abstr]. Circulation 1998; 98 (suppl.I): 1-300.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">AumègeatV, de Groote P, Meurice T et al. Aspirin and angiotensin converting enzyme inhibitors in 445 patients with moderate congestive heart failure [abstr].J Am Coll Cardiol 1999; 33 (suppl.A): 214A.</mixed-citation><mixed-citation xml:lang="en">AumègeatV, de Groote P, Meurice T et al. Aspirin and angiotensin converting enzyme inhibitors in 445 patients with moderate congestive heart failure [abstr].J Am Coll Cardiol 1999; 33 (suppl.A): 214A.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Moore SAt Steinhubl SR. Aspirin and ACE inhibitors in patients with heart failure: WATCHingfor a potential interaction. Heart Drug 2001; I: 169-75·</mixed-citation><mixed-citation xml:lang="en">Moore SAt Steinhubl SR. Aspirin and ACE inhibitors in patients with heart failure: WATCHingfor a potential interaction. Heart Drug 2001; I: 169-75·</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Беленков ЮН, Мареев BK). Принципы рационального лечения сердечной недостаточности.М: Медиа Медика, 2000; 266 с.</mixed-citation><mixed-citation xml:lang="en">Беленков ЮН, Мареев BK). Принципы рационального лечения сердечной недостаточности.М: Медиа Медика, 2000; 266 с.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hladovec J, Rossmann P. Circulating endothelial cells isolated together with platelets and the experimental modification of their count in rats. Thromb Res 1973; 3:663-74-</mixed-citation><mixed-citation xml:lang="en">Hladovec J, Rossmann P. Circulating endothelial cells isolated together with platelets and the experimental modification of their count in rats. Thromb Res 1973; 3:663-74-</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Иванова O.B.,Рогоза A.M. и др. Определение чувствительности плечевой артерии к напряжению сдвига на эндотелии как метод оценки состояния эндотелийзависимой вазодилатации с помощью ультразвука высокого разрешения у больных с артериальной гипертонией. Кардиология, 1998;3:37-42.</mixed-citation><mixed-citation xml:lang="en">Иванова O.B.,Рогоза A.M. и др. Определение чувствительности плечевой артерии к напряжению сдвига на эндотелии как метод оценки состояния эндотелийзависимой вазодилатации с помощью ультразвука высокого разрешения у больных с артериальной гипертонией. Кардиология, 1998;3:37-42.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Лагута П.С., Панченко Е.Л. Роль аспирина влечении и профилактике сердечно-сосудистых заболеваний (Обзор литературы). Mv 2002; 11 с.</mixed-citation><mixed-citation xml:lang="en">Лагута П.С., Панченко Е.Л. Роль аспирина влечении и профилактике сердечно-сосудистых заболеваний (Обзор литературы). Mv 2002; 11 с.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Shimokawa Т., Smith W.L. Prostaglandin endoperoxide synthase the aspirin acetilatyion region.JBiol Chem 1992; 267:12378.</mixed-citation><mixed-citation xml:lang="en">Shimokawa Т., Smith W.L. Prostaglandin endoperoxide synthase the aspirin acetilatyion region.JBiol Chem 1992; 267:12378.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Patrono C, Collar B, Dalen J et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998; 114:470S-488S.</mixed-citation><mixed-citation xml:lang="en">Patrono C, Collar B, Dalen J et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998; 114:470S-488S.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">FitzGerald GĄ Oates JA, Haunger J et al. Endogenous biosynthesis of prostacyclin and thromboxane and plateletfunction during chronic administration of aspirin in man. J Clin Invest 1983; 71:676-88.</mixed-citation><mixed-citation xml:lang="en">FitzGerald GĄ Oates JA, Haunger J et al. Endogenous biosynthesis of prostacyclin and thromboxane and plateletfunction during chronic administration of aspirin in man. J Clin Invest 1983; 71:676-88.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Madan ZM, Sainani GS. Effect of aspirin treatment on plasma levels of keto PGFI " and thromboxane B2.J Assoc Physicians India 1995; 43:597-9</mixed-citation><mixed-citation xml:lang="en">Madan ZM, Sainani GS. Effect of aspirin treatment on plasma levels of keto PGFI " and thromboxane B2.J Assoc Physicians India 1995; 43:597-9</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Chuang ML, Parker RA, Riley MF et al. Three demensional echocardiography improves accuracy and compensates for sonagrafter inexperience in assessment of left ventriculare ejection fraction. J Am Soc Ecbocardiogr 1999 May; 12: 290-9.</mixed-citation><mixed-citation xml:lang="en">Chuang ML, Parker RA, Riley MF et al. Three demensional echocardiography improves accuracy and compensates for sonagrafter inexperience in assessment of left ventriculare ejection fraction. J Am Soc Ecbocardiogr 1999 May; 12: 290-9.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Katz SD, Radin M, Graves T et al. Effect of aspirin and ifetroban on skeleta I muscle blood flow in patients with congestive heart failure treated ivith enalapril. f Am Coll Cardiol 1999; 34- 170-6.</mixed-citation><mixed-citation xml:lang="en">Katz SD, Radin M, Graves T et al. Effect of aspirin and ifetroban on skeleta I muscle blood flow in patients with congestive heart failure treated ivith enalapril. f Am Coll Cardiol 1999; 34- 170-6.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Davie AP, Love MP, McMurray JJ. Aspirin and aracbidonic acid in patients with heart failure [abstrj. Circulation 1998; 98 (suppl. I): 1-319</mixed-citation><mixed-citation xml:lang="en">Davie AP, Love MP, McMurray JJ. Aspirin and aracbidonic acid in patients with heart failure [abstrj. Circulation 1998; 98 (suppl. I): 1-319</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lyons D, Webster J, Benjamin N The effect of antihypertensive therapy on local intra-arterial NG-Monomethyl-L-Arginine in patients with essential hypertension, f Hypertens 1994; 12:1074-52.</mixed-citation><mixed-citation xml:lang="en">Lyons D, Webster J, Benjamin N The effect of antihypertensive therapy on local intra-arterial NG-Monomethyl-L-Arginine in patients with essential hypertension, f Hypertens 1994; 12:1074-52.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Felsch A, Schror R. Plateled activating factor-induced tissue injury in a neutrophil -perfused preparation is antogonised by bradykinin and ramiprilat. In: GB,Scholkens BA, Scicli AG. (eds). The role of bradykinin in the cardiovascular action of ramipril.MediaMedica, Sussex, 1992; 69-77-29- Vanhoutte PM. Other endothelium-derived vasoactive factors. Circ 1993; 87 (suppl. I): V9-V17-</mixed-citation><mixed-citation xml:lang="en">Felsch A, Schror R. Plateled activating factor-induced tissue injury in a neutrophil -perfused preparation is antogonised by bradykinin and ramiprilat. In: GB,Scholkens BA, Scicli AG. (eds). The role of bradykinin in the cardiovascular action of ramipril.MediaMedica, Sussex, 1992; 69-77-29- Vanhoutte PM. Other endothelium-derived vasoactive factors. Circ 1993; 87 (suppl. I): V9-V17-</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Vanhoutte PM, Boulanger C, Mombouli JV. Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 1995; 76:3E-12E.</mixed-citation><mixed-citation xml:lang="en">Vanhoutte PM, Boulanger C, Mombouli JV. Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 1995; 76:3E-12E.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Shimpo M, Ikeda U, Maeda Y et al. Effects of aspirin-like drugs on nitric oxide synthesis in rat vascular smooth muscle cells. Hypertension 2000; 35: 1085</mixed-citation><mixed-citation xml:lang="en">Shimpo M, Ikeda U, Maeda Y et al. Effects of aspirin-like drugs on nitric oxide synthesis in rat vascular smooth muscle cells. Hypertension 2000; 35: 1085</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Miller VM, Vanhoutte PM. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxigenase. Am f Physiol 1985; 248: H432-H437</mixed-citation><mixed-citation xml:lang="en">Miller VM, Vanhoutte PM. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxigenase. Am f Physiol 1985; 248: H432-H437</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Akiere Rf, Kiritsy-Roy JF, Catravas JD et al. Acetylcholine-induced contractions in isolated rabbit pulmonary arteries: role of troboxane A2.J Pharm Exp Ther 1986; 236:53541</mixed-citation><mixed-citation xml:lang="en">Akiere Rf, Kiritsy-Roy JF, Catravas JD et al. Acetylcholine-induced contractions in isolated rabbit pulmonary arteries: role of troboxane A2.J Pharm Exp Ther 1986; 236:53541</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Husain S, Andrews NP, Mulcahy Detal Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97: 716-20.</mixed-citation><mixed-citation xml:lang="en">Husain S, Andrews NP, Mulcahy Detal Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97: 716-20.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 97З-9.</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 97З-9.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Farivar S, Brecher P. Salicylate as a transcriptional inhibitor of inducible nitric oxyde syntase in cultured cardiac fibroblasts. J Biol Cbem 1996; 271 (49): 31585-92</mixed-citation><mixed-citation xml:lang="en">Farivar S, Brecher P. Salicylate as a transcriptional inhibitor of inducible nitric oxyde syntase in cultured cardiac fibroblasts. J Biol Cbem 1996; 271 (49): 31585-92</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">BolgerAP, Anker SD. Tumor necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 2000; 60 (6): 1245-57</mixed-citation><mixed-citation xml:lang="en">BolgerAP, Anker SD. Tumor necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 2000; 60 (6): 1245-57</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
